Oncolytics Biotech Inc T.ONC

Strategic Combinations: Future of OV therapy with reovirus

[Noteable]

https://mct.aacrjournals.org/content/15/5/767.short

September 29, 2021 -

"Reovirus, an orally administered oncolytic virus, also enhanced anti-tumor immunity in several preclinical studies [112,113,114]. In a preclinical study, the oral reovirus RC402 elicited potent and long-lasting anti-tumor immunity in distant tumors by enhancing the infiltration of CD8+ cytotoxic T cells and reducing Tregs. Moreover, RC402 cooperated with PD1 blockade to completely regress colon cancer and prolong the survival of tumor-bearing mice [114]. Parakrama et al. also reported that an intravenous administration of reovirus to patients with mCRC resulted in antigen-presenting cell stimulation and CD8+ T cell activation, which can be used as an immunomodulator [115]."

Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer

https://www.mdpi.com/2072-6694/13/19/4906/htm

[Noteable]

September 04, 2021 Reovirus sensitizes microsatellite stable colorectal cancer to anti-PD-1 treatment via cross-talk in innate and adaptive immune systems  View ORCID ProfileAuthors : Titto Augustine, Peter John, Tyler Friedman, Jeeshan Jiffry, Hillary Guzik, Rifat Mannan, Riya Gupta, Catherine Delano, John M.&

[Noteable]

October 07, 2021 - Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors T-Cell Infiltration and Activation Within the TME Are Key Drivers of Anti-tumor Immune Response [This work supports/confirms ONCY's TiLs clonality biomarker findings including that a major factor involved in initial resistance to immune

[Noteable]

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors T-Cell Infiltration and Activation Within the TME Are Key Drivers of Anti-tumor Immune Response [This work supports/confirms ONCY's TiLs clonality biomarker findings including that a major factor involved in initial resistance to immune checkpoint inhibitors

[Noteable]

And here is just one of my many posts from 2.5 years ago in a further attempt to educate those who appear on this and other ONCY message boards - and now is coming to fruition through ONCY's GOBLET-1 results, including anal cancers.

[Noteable]

Just to remind you what I said 2.5 years ago ... September 29, 2021 -   "Reovirus, an orally administered oncolytic virus, also enhanced anti-tumor immunity in several preclinical studies [112,113,114]. In a preclinical study, the oral reovirus RC402 elicited potent and long-lasting anti-tumor immunity in distant tumors by enhancing the infiltration of CD8+ cytotoxic T cells and

[Noteable]

So currently pelareorep is administered as an intravenously delivered therapy.. but there may also be the potential to provide pelareorep orally if the issue of celiac disease can be aborted.

[13X2413]

You're making it sound like it's a good thing that you were educating everyone 2.5 years ago. You do realize that the stock is sitting stagnant at $1.40 and change?

[Noteable]

Are you one of those mining and energy traders who have been sitting on the share price?

[Lesalpes29]

13X unstable is a broken AI algorithm out of control! 10B are coming sit tight!

[13X2413]

No, just a guy that hoped to make money. Now I'm just hoping to recoup some loss. 

[m00nsh0ts]

Does anybody have any idea of how any of the mouse studies on Pelareorep compare to the actual human studies that followed?. Is there a positive correlation?